Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19498569 | 0.87 | HPGDS (0.34) | CHRM3PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL19498195 | 0.84 | PDE10A (0.40) | PDE10AMAP4K4 | |
| SCHEMBL19498181 | 0.81 | HTR2A (0.42) | HTR2AHTR2C | |
| SCHEMBL19498194 | 0.78 | GAA (0.43) | KMT2AHTR2AHTR2C | |
| SCHEMBL19498171 | 0.77 | TSHR (0.37) | KMT2A | |
| SCHEMBL19498162 | 0.72 | CYP1A2 (0.32) | HTR2AHTR2C | |
| SCHEMBL19498567 | 0.70 | ABHD6 (0.43) | HTR2AHTR2C | |
| SCHEMBL16639804 | 0.70 | DRD2 (0.34) | — | |
| SCHEMBL17624445 | 0.69 | HTR2A (0.36) | CHRM3PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL19498186 | 0.68 | NCF1 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170305922-A1 | CARM1 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170305922-A1 | CARM1 INHIBITORS AND USES THEREOF | CARM1, ADRM1, PRMT1 | CHRM3 2332/4885PDE4A 1616/4885PDE4B 1738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.